Dechert advised Abivax on the deal. Abivax, a Euronext Paris listed clinical-stage biotechnology company, executed its oversubscribed capital increase of €60 million and convertible bonds of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
